Ros Glasspool
罗斯·格拉斯普尔
MB ChB, PhD, FRCP
Consultant Medical Oncologist; Reader in Oncology, University of Glasgow肿瘤科顾问医师；格拉斯哥大学肿瘤学高级讲师
👥Biography 个人简介
Ros Glasspool, MB ChB PhD FRCP is a consultant oncologist at Beatson Cancer Centre and a leading UK investigator in endometrial and ovarian cancer clinical trials, with expertise in PARP inhibitors, homologous recombination deficiency, and gynecologic immunotherapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PARP Inhibitor Trials in Gynecologic Cancers
Served as UK PI for major PARP inhibitor trials in ovarian and endometrial cancers, characterizing HRD biomarkers and extending PARP inhibitor use to endometrial cancer clinical investigation.
Gynecologic Oncology Clinical Trial Access in UK
Led Cancer Research UK and NIHR-funded trials at Beatson, expanding access to novel immunotherapy and targeted agent combinations for Scottish and UK patients with endometrial cancer.
Representative Works 代表性著作
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1)
Lancet Oncology (2017)
Co-investigator on ARIEL2 defining HRD genomic biomarkers including BRCA mutation and loss of heterozygosity to identify patients most likely to respond to rucaparib.
Immunotherapy combinations in endometrial cancer: translational biomarker analysis
Gynecologic Oncology (2022)
Translational analysis identifying predictive biomarkers for immunotherapy response in endometrial cancer, supporting UK clinical trial development.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗斯·格拉斯普尔 的研究动态
Follow Ros Glasspool's research updates
留下邮箱，当我们发布与 Ros Glasspool（Beatson West of Scotland Cancer Centre / University of Glasgow）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment